Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT).

Wolfgang Mueck; Giancarlo Agnelli; Harry R. Büller

doi:10.1182/blood.v110.11.1880.1880

Related publications

Article2016

Guidance for the treatment of deep vein thrombosis and pulmonary embolism

Michael B. Streiff, Giancarlo Agnelli, Jean M. Connors, Mark Crowther, Sabine Eichinger, Renato D. Lópes, Robert D. McBane, Stephan Moll, Jack Ansell

Article2007

Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug‐resistant falciparum malaria

Elizabeth A. Ashley, Kasia Stepniewska, Niklas Lindegårdh, Rose McGready, Anna Annerberg, Robert Hutagalung, Thida Singtoroj, Gilvary Hla, Al Brockman, Stéphane Proux, Jahser Wilahphaingern, Pratap Singhasivanon, Sir Nicholas White, François Nosten

Tropical Medicine & International Health

Corrigendum2016

Erratum to: Guidance for the treatment of deep vein thrombosis and pulmonary embolism

Michael B. Streiff, Giancarlo Agnelli, Jean M. Connors, Mark Crowther, Sabine Eichinger, Renato D. Lópes, Robert D. McBane, Stephan Moll, Jack Ansell

Article2025

554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)

Andrew Garton, Vinu Menon, Hang Quach, Amit Khot, Bradley Augustson, Hanlon Sia, Nicole Wong Doo, David Levitz, Eben I. Lichtman, Michaela Liedtke, Camille Martinet, Beata Holkova, Harjeet Sembhi, Lida Pacaud, Sunitha Gn, Maria Pihlgren, Mario Perro, Cyril Konto

Article2017

The Comparison of EQ-5D-5L Versus Disease/Treatment-Specific Measures in Pulmonary Embolism and Deep Vein Thrombosis

Ling‐Hsiang Chuang, AT Cohen, Giancarlo Agnelli, PD Gumbs, Rupert Bauersachs, Sonja Kroep, Patrick Mismetti, A. K. Gitt, Manuel Monréal, SN Willich, Ben van Hout